Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, randomized, Phase 2/3 study in patients with locally
recurrent or metastatic triple-negative breast cancer (TNBC) with no more than one prior
systemic therapy for locally recurrent or metastatic disease.